HotmailProstate drug shows promise in early testing
New approach to fighting cancer was successful in 13 of 30 patients in trial
 | FirstPerson |
 | Standing up to cancer TODAY viewers who have battled breast cancer share their stories of survival and lessons learned. |
| Quiz |
 | What do you know about breast cancer? How old was Betty Ford when she had a mastectomy? How many women are affected by the disease each year? Take our iCue video quiz and find out. TODAY |
Join the Army of Women |
A message from Dr. Susan Love, MD The time has come for all women to stand up and say that we are not going to take it anymore! Breast cancer does not have to go on to another generation; we can be the ones who stop it once and for all! Join the Love/Avon Army of Women for you mother, sister, friend and daughter so that no one ever has to hear the words “you have breast cancer” again! Video: Dr. Love announces her Army of Women initiative on TODAY |
 | Slide show |
 | Famous breast cancer survivors Actresses, singers and a politician’s wife who’ve all been diagnosed with the disease reveal their strength to keep fighting. more photos |
 | Breast cancer videos |
 TODAY Look and feel your best after cancer Oct. 27: Three experts share advice for breast cancer survivors on coping with the appearance-related side effects of breast cancer treatment. |
WASHINGTON - Early trials of a new drug for advanced prostate cancer are showing some success, researchers report.
Of the first 30 patients treated with MDV3100, 13 showed declines of more than 50 percent in the levels of chemicals in the blood that indicate the presence of the cancer.
However, the tests are only in phase 1 and 2, where drugs are checked for safety, side effects and early indications of effectiveness. The drug still faces a larger phase 3 tests of effectiveness before it can be proposed for use.
The preliminary findings, by a team led by Charles L. Sawyers of Memorial Sloan-Kettering Cancer Center in New York, are reported in Friday's edition of the journal Science.
The treatment is for prostate cancer that has metastasized, or spread to other areas of the body.
Men with these cancers are often treated with drugs that inhibit the activity of male hormones, which can drive tumor growth. But tumors can become resistant to those drugs.
The new one binds to receptors for the male hormones, thus retaining the anticancer activity, the researchers report.
- Discuss Story On Newsvine
-
Rate Story:
View popularLowHigh - Instant Message
MORE FROM HEALTH |
 Health Section Front |
| Add Health headlines to your news reader: |
Sponsored links
Resource guide